Crossing barriers from blood-to-brain and academia-to-industry

Therapeutic Delivery

Volumn 1, Issue 4, 2010, Pages 495-500

  Gaillard, Pieter J ^a  

^a Bio Partner Center II   (Netherlands)

Author keywords

blood brain barrier; brain disease; drug delivery; drug targeting; neuroscience

Indexed keywords

DOXORUBICIN; DRUG CARRIER; GLUTATHIONE; HYBRID PROTEIN; LIPOSOME; NANOPARTICLE; RIBAVIRIN;

ACUTE DISEASE; BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC DISEASE; COST CONTROL; DRUG ACTIVITY; DRUG BRAIN LEVEL; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG MARKETING; DRUG PENETRATION; DRUG SAFETY; DRUG TARGETING; ENCAPSULATION; HUMAN; LIGAND BINDING; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; REVIEW; RISK ASSESSMENT;

EID: 79954499805     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.10.43     Document Type: Review

References (25)

1. The Neurotechnology Industry 2008 Report. Pub ID: NEI1781046. NeuroInsights, LLC. May 8 (2008).
2. Pardridge WM. Drug and gene delivery to the brain: the vascular route. Neuron 36(4), 555-558 (2002). (Pubitemid 35346750)
3. Gaillard PJ, Visser CC, de Boer AG. Targeted delivery across the blood-brain barrier. Expert Opin. Drug Deliv. 2(2), 299-309 (2005). (Pubitemid 41130884)
4. Bellavance MA, Blanchette M, Fortin D. Recent advances in blood-brain barrier disruption as a CNS delivery strategy. AAPS. J. 10(1), 166-177 (2008).
5. de Boer AG, Gaillard PJ. Drug targeting to the brain. Annu. Rev. Pharmacol. Toxicol. 47, 323-355 (2007).
6. de Boer AG, van der Sandt IC, Gaillard PJ. The role of drug transporters at the blood-brain barrier. Annu. Rev. Pharmacol. Toxicol. 43, 629-656 (2003). (Pubitemid 37372656)
7. Gabathuler R. Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases. Neurobiol. Dis. 37(1), 48-57 (2010).
8. Jones AR, Shusta EV. Blood-brain barrier transport of therapeutics via receptor-mediation. Pharm. Res. 24(9), 1759-1771 (2007). (Pubitemid 47206625)
9. Pardridge WM. Brain drug development and brain drug targeting. Pharm. Res. 24(9), 1729-1732 (2007). (Pubitemid 47206626)
10. Pardridge WM. Drug targeting to the brain. Pharm. Res. 24(9), 1733-1744 (2007). (Pubitemid 47206623)
11. Rip J, Schenk GJ, de Boer AG. Differential receptor-mediated drug targeting to the diseased brain. Expert Opin. Drug Deliv. 6(3), 227-237 (2009).
12. Bickel U, Yoshikawa T, Pardridge WM. Delivery of peptides and proteins through the blood-brain barrier. Adv. Drug Deliv. Rev. 46(1-3), 247-279 (2001).
13. Lu W, Wan J, She Z, Jiang X. Brain delivery property and accelerated blood clearance of cationic albumin conjugated pegylated nanoparticle. J. Control. Release 118(1), 38-53 (2007). (Pubitemid 46283096)
14. Pardridge WM. Blood-brain barrier drug targeting: the future of brain drug development. Mol. Interv. 3(2), 90-105 (2003).
15. Kannan R, Chakrabarti R, Tang D, Kim KJ, Kaplowitz N. GSH transport in human cerebrovascular endothelial cells and human astrocytes: evidence for luminal localization of Na+-dependent GSH transport in HCEC. Brain Res. 852(2), 374-382 (2000). (Pubitemid 30035175)
16. Kannan R, Kuhlenkamp JF, Jeandidier E et al. Evidence for carrier-mediated transport of glutathione across the blood-brain barrier in the rat. J. Clin. Invest. 85(6), 2009-2013 (1990). (Pubitemid 20192980)
17. Zlokovic BV, Mackic JB, McComb JG et al. Evidence for transcapillary transport of reduced glutathione in vascular perfused guinea-pig brain. Biochem. Biophys. Res. Commun. 201(1), 402-408 (1994). (Pubitemid 24213740)
18. van Tellingen O, Brandsma D, Appeldoorn CCM et al. GSH-conjugation improves efficacy of Doxil against intracranial xenografts. Presented at: 101st Annual Meeting of the American Association for Cancer Research. Washington DC, PA, USA, 17-21 April 2010.
19. Rip J, Appeldoorn CCM, Manca FM et al. Receptor-mediated delivery of drugs across the blood-brain barrier. Presented at: Pharmacology and Toxicology of the Blood-brain Barrier: State of the Art, Needs for Future Research and Expected Benefits for the EU. Brussels, Belgium, 11-12 February 2010.
20. Block KI, Koch AC, Mead MN et al. Impact of antioxidant supplementation on chemotherapeutic toxicity: a systematic review of the evidence from randomized controlled trials. Int. J. Cancer. 123(6), 1227-1239 (2008).
21. Brasnjevic I, Steinbusch HW, Schmitz C, Martinez-Martinez P. Delivery of peptide and protein drugs over the blood-brain barrier. Prog. Neurobiol. 87(4), 212-251 (2009).
22. Woodle MC, Lasic DD. Sterically stabilized liposomes. Biochim. Biophys. Acta 1113(2), 171-199 (1992).
23. Gaillard PJ, Visser CC, Appeldoorn CCM, Rip J. Blood-to-brain drug delivery - 10 key development criteria. Curr. Pharm. Biotechnol. (2010) (In Press).
24. Industrial Technology Research Institute. US20070141133 (2005).
25. to-BBB technologies B.V: Dutch biotechnology company in the field of enhanced drug delivery across the blood-brain barrier www.toBBB.com